So here we are. Nearly two years in the making, much of it focused, fastidious work by founder Jennifer Petter (of whom much more below), capped by an exhilarating and exhausting sprint to the finish by an outstanding team, Arrakis Therapeutics has now lifted off. Today we announced a $38M Series A financing led by […]
Dark Matter Blog
Archive for February, 2017
Discovering a New World of RNA-Targeted Medicines
February 27th, 2017
by Michael Gilman, PhD
CEO, Arrakis
by Michael Gilman, PhD
CEO, Arrakis
Escaping the Gravitational Pull of “Druggability”
February 22nd, 2017
by Michael Gilman, PhD
CEO, Arrakis
by Michael Gilman, PhD
CEO, Arrakis
Most old-timers in drug discovery will agree on one thing: It never gets easier. Sure, maybe we learn a little from our mistakes along the way and the toolkit gets steadily flashier. But the easy targets, if ever they were truly easy ones, are long gone. We are left with either inscrutable biology or, even […]